Results 131 to 140 of about 69,031,262 (351)

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

COVID‐19: A systematic review and update on prevention, diagnosis, and treatment

MedComm, 2022
Since the rapid onset of the COVID‐19 or SARS‐CoV‐2 pandemic in the world in 2019, extensive studies have been conducted to unveil the behavior and emission pattern of the virus in order to determine the best ways to diagnosis of virus and thereof ...
Hooman Aghamirza Moghim Aliabadi, Reza Eivazzadeh‐Keihan, Arezoo Beig Parikhani, Sara Fattahi Mehraban, Ali Maleki, Sepideh Fereshteh, Masoume Bazaz, Ashkan Zolriasatein, Bahareh Bozorgnia, Saman Rahmati, Fatemeh Saberi, Zeinab Yousefi Najafabadi, Shadi Damough, Sara Mohseni, Hamid Salehzadeh, Vahid Khakyzadeh, Hamid Madanchi, Gholam Ali Kardar, Payam Zarrintaj, Mohammad Reza Saeb, Masoud Mozafari   +20 more
doaj   +1 more source

Covid-19 treatment update: follow the scientific evidence

Journal of Thrombosis and Thrombolysis, 2020
The Covid (coronavirus-associated disease)-19 pandemic continues to grip the world in both overt and covert waysnot unexpected from a nearly invisible (0.1 μm RNA virus) and sinister foe with light-speed mutation rates and hostswitching capabilities [1].
R. Becker
semanticscholar   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

The role of nutrition on the treatment of Covid 19

Human Nutrition & Metabolism
The rapid and extensive transmission of the SARS-CoV-2 virus has led to a worldwide COVID-19 pandemic. Initially thought to be an acute illness, many patients have reported persistent and recurring symptoms even after the infectious period.
Samer Younes
doaj   +1 more source

Covid-19 Therapy: What Have We Learned In 8 Months?

Postępy Mikrobiologii, 2020
SARS-CoV-2, a novel pathogenic human coronavirus, emerged in December of 2019 in Wuhan (Hubei province, China). In most cases, the infection causes a mild to moderate respiratory illness.
Adamczyk-Popławska Monika, Kwiatek Agnieszka   +1 more
doaj   +1 more source

Lactoferrin for the treatment of COVID‑19 (Review)

Experimental and Therapeutic Medicine, 2020
The coronavirus disease 2019 (COVID-19) outbreak was caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical outcomes of elderly individuals and those with underlying diseases affected by COVID-19 are serious, and may result in acute respiratory distress syndrome (ARDS) and even mortality.
Wang, Yidan, Wang, Puxiu, Wang, Haoran, Luo, Yifan, Wan, Long, Jiang, Mingyan, Chu, Yang   +6 more
openaire   +3 more sources

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers, Yaqiao Wei, Dinesh K. Deelchand, Adam Berrington, Young Woo Park, Guita Banan, Michal Povazan, Jens T. Rosenberg, André J. W. van der Kouwe, Tetsuo Ashizawa, Khalaf O. Bushara, Chiadi U. Onyike, Sub H. Subramony, Jeremy D. Schmahmann, Brian J. Soher, Peter B. Barker, Thomas H. Mareci, Eva‐Maria Ratai, Lynn E. Eberly, Gülin Öz   +19 more
wiley   +1 more source

COVID‐19 treatment by repurposing drugs until the vaccine is in sight

Drug development research (Print), 2020
Corona virus disease (COVID‐19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS‐CoV 2 virus and has affected large populations in over 120 countries.
M. Phadke, S. Saunik
semanticscholar   +1 more source

Factors Associated With the Rising Trend in Self‐Reported Cognitive Disability Among U.S. Adults Aged 18–39 From 2013–2024

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Building on our prior Behavioral Risk Factor Surveillance System analysis identifying adults aged 18–39 as the primary driver of the national increase in self‐reported cognitive disability, we examined factors associated with this rise using 2013–2024 U.S. BRFSS data. Methods We analyzed U.S.
Adam de Havenon, Ka‐Ho Wong, Mirriam Mananah, Christopher D. Anderson, Ada Fenick, Amy Arnsten, Arman Fesharaki‐Zadeh, James C. McPartland, Mary L. Adams, Kevin N. Sheth   +9 more
wiley   +1 more source